| 2025-09-09 |
Partner Therapeutics, Inc. |
Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS]) partnertx.com ↗ |
| 2025-06-20 |
Partner Therapeutics, Inc. |
European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome) partnertx.com ↗ |
| 2025-01-09 |
Partner Therapeutics, Inc. |
BARDA and Partner Therapeutics continue partnership around development of LEUKINE® (sargramostim, rhu GM-CSF) to potentially improve patient care for sepsis partnertx.com ↗ |
| 2024-04-18 |
Partner Therapeutics, Inc. |
Comprehensive Review Highlights Potential Benefits of Leukine® in Management of Gastrointestinal (GI) Adverse Events Associated with Immune Checkpoint Inhibitors (ICIs) in the Treatment of Cancer partnertx.com ↗ |
| 2024-04-03 |
Partner Therapeutics, Inc. |
Partner Therapeutics’ Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP) partnertx.com ↗ |
| 2024-01-17 |
Partner Therapeutics, Inc. |
Comprehensive Review Highlights Importance of Leukine® in Combination with Anti-GD2 Immunotherapy for Treatment of High-Risk Pediatric Neuroblastoma partnertx.com ↗ |
| 2023-12-20 |
Partner Therapeutics, Inc. |
Exploratory Results Suggest the Potential Role of LEUKINE ® as a Host-Directed Immunomodulator partnertx.com ↗ |
| 2023-11-30 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Publication of 30-month Randomized Open Label Study of LEUKINE® in Combination with Whole Lung Lavage for Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) partnertx.com ↗ |
| 2022-12-15 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Publication of a Retrospective Cohort Review of 15 LEUKINE® Treated Patients with Pediatric Malignancies and Invasive Fungal Disease Refractory to Antifungal Therapy partnertx.com ↗ |
| 2022-02-17 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine® to Treat Sulfur Mustard Gas (HD) Exposure partnertx.com ↗ |
| 2021-09-20 |
Partner Therapeutics, Inc. |
BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients partnertx.com ↗ |
| 2021-08-17 |
Partner Therapeutics, Inc. |
“A Drug Before Its Time?” LEUKINE® systematic review highlights innate and adaptive immune activity that may improve cancer outcomes and reduce toxicity partnertx.com ↗ |
| 2021-06-28 |
Partner Therapeutics, Inc. |
Second Randomized Trial of Leukine® (sargramostim) in COVID-19 Demonstrates Improvement in Lung Function partnertx.com ↗ |
| 2021-05-19 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine® (sargramostim) in Patients with Parkinson’s Disease partnertx.com ↗ |
| 2021-04-29 |
Partner Therapeutics, Inc. |
Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in High-risk Non-hospitalized COVID-19 Patients (SCOPE) partnertx.com ↗ |
| 2021-03-24 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer’s Disease partnertx.com ↗ |
| 2021-02-26 |
Partner Therapeutics, Inc. |
SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function partnertx.com ↗ |
| 2021-02-18 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine® Improves Survival in Acute Radiation Syndrome (ARS) partnertx.com ↗ |
| 2020-09-11 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma partnertx.com ↗ |
| 2020-08-25 |
Partner Therapeutics, Inc. |
Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in COVID-19 Patients partnertx.com ↗ |
| 2020-08-04 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces $35 Million Contract with U.S. Department of Defense for Advanced Development and Emergency Use of Leukine® (rhuGM-CSF) for COVID-19 Acute Hypoxemic Respiratory Failure (AHRF) partnertx.com ↗ |
| 2020-06-11 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Initiation of Clinical Trial Evaluating Leukine® in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant partnertx.com ↗ |
| 2020-05-28 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Respiratory Illness in Patients with COVID-19 at Singapore General Hospital partnertx.com ↗ |
| 2020-03-24 |
Partner Therapeutics, Inc. |
Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Patients with COVID-19 Associated Respiratory Illness partnertx.com ↗ |
| 2019-09-19 |
Partner Therapeutics, Inc. |
Partner Therapeutics Receives Orphan Drug Designation for Leukine® (sargramostim) partnertx.com ↗ |
| 2018-11-06 |
Partner Therapeutics, Inc. |
Partner Therapeutics Receives FDA Orphan Drug Designation for Leukine® for the Treatment of Pulmonary Alveolar Proteinosis partnertx.com ↗ |
| 2018-06-06 |
Partner Therapeutics, Inc. |
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome partnertx.com ↗ |
| 2018-05-24 |
Partner Therapeutics, Inc. |
Tanner Pharma Group Signs a Distribution Agreement for Partner Therapeutics’ Product, Leukine® partnertx.com ↗ |
| 2018-02-01 |
Partner Therapeutics, Inc. |
Partner Therapeutics (PTx) Acquires Leukine® from Sanofi partnertx.com ↗ |
|